{"request_id":"1903e309ff57e6f4f2b3ed34f0e42b0b","results":{"ticker":"REGN","name":"Regeneron Pharmaceuticals Inc","market":"stocks","locale":"us","primary_exchange":"XNAS","type":"CS","active":true,"currency_name":"usd","cik":"0000872589","composite_figi":"BBG000C734W3","share_class_figi":"BBG001S6PX49","market_cap":83735822622.0,"phone_number":"(914) 847-7000","address":{"address1":"777 OLD SAW MILL RIVER ROAD","city":"TARRYTOWN","state":"NY","postal_code":"10591"},"description":"Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).","sic_code":"2834","sic_description":"PHARMACEUTICAL PREPARATIONS","ticker_root":"REGN","homepage_url":"https://www.regeneron.com","total_employees":14176,"list_date":"1991-04-02","branding":{"logo_url":"https://api.polygon.io/v1/reference/company-branding/cmVnZW5lcm9uLmNvbQ/images/2024-10-01_logo.svg","icon_url":"https://api.polygon.io/v1/reference/company-branding/cmVnZW5lcm9uLmNvbQ/images/2024-10-01_icon.jpeg"},"share_class_shares_outstanding":108070000,"weighted_shares_outstanding":109889531,"round_lot":100},"status":"OK"}
